Tags : Yangtze River

Biosimilars

Alvotech and Alvotech & CCHT Sign an Exclusive Commercialization Agreement

Shots: The companies collaborate with the Yangtze to commercialize eight biosimilars in China. The initial pipeline contains biosimilar candidates for the treatment of autoimmunity, ophthalmology, and oncology Alvotech and Alvotech & CCHT will be jointly responsible for the development, registration, and supply of biosimilars in China while Yangtze River Pharmaceutical will exclusively commercialize the biosimilars […]Read More